Get involved in research and clinical trials
Drug and Alcohol Services South Australia (DASSA) supports research projects including clinical trials which aim to find new and improved prevention and treatment models to support those affected by an alcohol or other drug problem.
DASSA is actively seeking participants to be involved in the following clinical trials.
The LiMA Study: A study of lisdexamfetamine for the treatment of methamphetamine dependence.
Australia has one of the highest rates of methamphetamine dependence in the world. While counselling is effective for many people with less severe dependence, there is no proven medication treatment for severe dependence.
This study aims to test the effectiveness of a new medication which could assist in treating methamphetamine dependence.
Drug and Alcohol Services South Australia (DASSA) is looking for current methamphetamine users over the age of 18 to be involved in a clinical trial held at DASSA Central Services in Stepney or DASSA Northern Services in Elizabeth. Participation is voluntary.
Recruitment is now open.
Please phone Alcohol and Drug Information Service (ADIS) on 1300 131 340 if you would like to know more or check the study website: The Lima Study
Human Research Ethics Committee, Reference number: HREC/16/SVH/222
Treatment Centre Study
DASSA is participating in a national study, ‘Alcohol Treatment Centre Study’ which aims to improve alcohol treatment outcomes for people seeking help with alcohol problems:
DASSA believes this is important research and we would encourage you to participate in the study if you want to. Participation is voluntary, and involves the completion of an initial survey and follow up survey in three months’ time.
This study is the first of its kind nationally, and aims to determine the individual, treatment and system-level factors associated with successful treatment for alcohol dependence. This research could significantly improve our current understanding about how treatment outcomes for alcohol dependent patients can be optimised.
We are looking for adults seeking outpatient based treatment for alcohol use at DASSA Central and Southern Services.
Recruitment is now open.
Please phone DASSA Research Governance Officer (08) 7425 5121 if you would like to know more.
Human Research Ethics Committee (Reference number 16/05/18/4.07)
Clinical trial of nicotine vaporisers added to standard
care for smoking cessation and relapse prevention (CARP)
DASSA is involved in a multi-site trial coordinated through the University of Queensland and funded by the National Health and Medical Research Centre (NHMRC). The research will test the use of nicotine vaporisers as a quit smoking aid for people with certain medical conditions with a focus on people with Hepatitis C, HIV, or Opiate Dependence.
Participants in the intervention side of the study will be provided with the nicotine vaporiser for use for 12 weeks at no cost and asked to use it in conjunction with Quitline counselling and nicotine patches.
Other participants will aim to make a quit attempt with support provided by Quitline and provided with nicotine patches and their choice of nicotine lozenges or nicotine gum. They will receive the nicotine vaporiser after the first 6 months to make a second quit attempt if their first quit attempt was unsuccessful.
To pre-register to check your eligibility and reserve a place visit website: Cessation and Relapse Prevention (CARP) Clinical Trial or call 1800 290 689.
Human Research Ethics Committee reference number: HREC/17/QPCH/422